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Resistant hypertension is a failure to achieve goal BP (<140/90mmHg for the overall population and <130/80mmHg for those
with diabetes mellitus or chronic kidney disease) in a patient who adheres to maximum tolerated doses of 3 antihypertensive
drugs including a diuretic. The kidneys play a critical role in long-term regulation of blood pressure. Blunted pressure natriuresis,
with resultant increase in extracellular ﬂuid volume, is an important cause of resistant hypertension. Activation of the renin-
angiotensin-aldosterone system, increased renal sympathetic nervous system activity and increased sodium reabsorption are
important renal mechanisms. Successful treatment requires identiﬁcation and reversal of lifestyle factors or drugs contributing to
treatmentresistance,diagnosisandappropriatetreatmentofsecondarycausesofhypertension,useofeﬀectivemultidrugregimens
and optimization of diuretic therapy. Since inappropriate renal salt retention underlies most cases of drug-resistant hypertension,
the therapeutic focus should be on improving salt depleting therapy by assessing and, if necessary, reducing dietary salt intake,
optimizing diuretic therapy, and adding a mineralocorticoid antagonist if there are no contraindications.
1.Introduction
The Joint National Committee (JNC) 7 deﬁned resistant
hypertension as failure to achieve goal blood pressure
(BP) (<140/90mmHg for the overall population and
<130/80mmHg for those with diabetes mellitus or chronic
kidney disease) in a patient who adheres to maximum
tolerated doses of 3 antihypertensive drugs including a
diuretic. An increasing number of patients, especially the
aged, those with diabetes or who are African American,
meet this deﬁnition. However, it is important to rule out
white coat hypertension by asking the patient to record their
own home blood pressures and undertaking an ambulatory
blood pressure monitor if the results are equivocal. A
careful enquiry about whether the patient is taking the
prescribed medications and if there are adverse eﬀects that
are causing concern may give clues to noncompliance. In
some cases, it may be useful to measure blood or urine drug
levels, for example of diuretics, to check for noncompliance.
A recent study of African Americans with hypertensive
focal segmental glomerulosclerosis [1] has linked a single
nucleotide polymorphism for the apolipoprotein L1 gene to
the disease but this is not yet available as a diagnostic test.
Since aging increases the burden of vascular disease, resistant
hypertension and its consequences are more common in
elderly people. The kidneys play a critical role in long term
regulation of blood pressure. In this paper, we discuss the
renal mechanisms which contribute to the development of
resistanthypertension,whicharesummarizedinTable 1,and
their management.
2.Blunted PressureNatriuresis
Pressure natriuresis [2] describes the increased sodium
excretion that occurs with elevated blood pressure. A normal
pressure natriuresis should prevent hypertension because
any elevation of blood pressure would elicit an increased
sodium and water excretion that would reduce the blood
v o l u m ea n dv e n o u sr e t u r na n dr e t a i nan o r m a ll e v e lo fb l o o d
pressure.Patientswithhypertensionhaveadefectivepressure
natriuresis. The relationship between sodium excretion and
blood pressure is shifted to higher levels of blood pressure,
which implies an abnormal response in the kidney that2 International Journal of Hypertension
Table 1: Renal mechanisms of drug-resistant hypertension.
(1) Blunted pressure natriuresis
(a) Chronic kidney disease
(b) Renal artery stenosis
(2) Renal nerve activation
(3) Renal nitric oxide deﬁciency
(4) Medications acting adversely on the kidney
(a) Non steroid anti inﬂammatory drugs (NSAIDs)
(b) Cox-2 inhibitors
(c) Corticosteroids
(d) Cyclosporine
(e) Erythropoietin
(f) Licorice
(5) Extra renal factors causing salt retention
(a) Hyperaldosteronism
(b) Vasodilator medications
(c) Obstructive sleep apnea (OSA)
(d) Endothelin type A receptor antagonists.
(6) Inappropriately high salt intake
(7) Ineﬀective diuretic usage
maintains hypertension. Salt retention occurs when intake
exceeds excretion. This leads to extracellular ﬂuid (ECF)
volume expansion which is common in chronic kidney
disease (CKD) and is an important cause of resistant
hypertension. The salt retention is typically subtle and does
not lead to edema. Even a normal rate of sodium excretion
in a patient with hypertension is inappropriate and implies
a renal mechanism of hypertension since a normal kidney
increasesthesodiumexcretionaboveintakeandreducesECF
volume when blood pressure is increased to restore a normal
levelofBP.Themechanismofrenalsodiumretentionusually
entails a combination of reduced glomerular ﬁltration rate
(GFR) and increased tubular sodium reabsorption. Since
the GFR may be normal or only reduced modestly, the
renal defect in resistant hypertension is predominantly a fail-
ure to appropriately suppress tubular sodium reabsorption
[3].
LargeincreasesinECFvolumemayariseifsodiumintake
is very high or reduction in GFR is severe (e.g., chronic
kidney disease stage 4-5). Patients with resistant hyperten-
sion had higher brain natriuretic peptide (BNP) and atrial
natriuretic peptide (ANP) levels conﬁrming that they had
increased intrathoracic blood volume [4].
Heartfailuremayaggravatesodiumretention.Drugsthat
include ﬂudrocortisone (mineralocorticoid receptor ago-
nist), estrogens, and nonsteroidal antiinﬂammatory drugs
(NSAIDS) [5] cause sodium retention and therefore are
important renal causes of resistant hypertension.
Other renal mechanisms implicated in the pathogen-
esis of resistant hypertension include: increased renin-
angiotensin-aldosterone system (RAAS) activity, increased
renal sympathetic nervous system (SNS) activity, nitric
oxide (NO) deﬁciency, oxidative stress, renal artery stenosis,
hyperaldosteronism, obstructive sleep apnea and vasodilator
medications (Table 1).
An important renal mechanism of resistant hypertension
is renal artery stenosis. As ﬁrst described by Goldblatt
[6] in animal models, the reduction in renal perfusion
pressure increases renin release by the kidney perfused by
the stenosed artery. The ensuing increases in angiotensin II
and aldosterone cause vasoconstriction and inappropriate
renal salt retention. Moreover, the kidney downstream from
the stenosis has a reduced renal perfusion pressure which
is a further potent mechanism for salt retention. Numer-
ous studies established the causal relationship between
angiotensin II–mediated vasoconstriction and hypertension
in the early phase of experimental renovascular hypertension
[7, 8]. The high levels of angiotensin II stimulate the
adrenal cortex to produce excessive aldosterone (secondary
aldosteronism), promoting renal sodium retention by both
kidneys. Moreover, angiotensin directly enhances renal salt
and ﬂuid reabsorption. Both the direct pressor eﬀects of
angiotensin II and the sodium retention restore the renal
perfusion pressure at the stenosed kidney at the expense of
systemic hypertension. However, during the chronic phase
of experimental renovascular hypertension, which may be a
better model for many patients with prolonged renal artery
stenosis, plasma renin activity returns to baseline levels.
The hypertension is sustained by hypertensive damage in
the contralateral kidney. This may explain the disappointing
results of controlled trials of renal revascularization of the
stenosed kidney [9, 10]. The recently published STAR [11]
trial, reported no overall beneﬁt in renal function in patients
with renal artery stenosis randomized to intervention,
compared to the control group that received medication
only. However, the number of antihypertensive medications
taken by the patients was reduced after intervention. The
CORAL [12] study is testing the eﬀect of intervention
for patients with renal artery stenosis on cardiovascular
events, but it is not yet completed. Another trial, RAS-
CAD [13] is studying the eﬀect of medical therapy alone
versus medical therapy plus renal artery stenting on left
ventricular hypertrophy progression (primary end point)
and cardiovascular morbidity and mortality (secondary end
points) in patients aﬀected by ischemic heart disease and
renal artery stenosis.
Patients with bilateral renal artery stenosis are at an
increased risk for developing severe renal salt retention. If
the stenosis is unilateral, the unaﬀected kidney can eliminate
the salt and water retained by the stenosed kidney via the
pressure natriuresis mechanism. However, if both kidneys
have a functional stenosis, the pressure natriuresis may be
curtailed suﬃciently to lead to episodic ﬂuid retention that
causes ﬂash pulmonary edema.
Clues to the presence of bilateral renal artery steno-
sis in resistant hypertension include an abdominal bruit,
atherosclerosis elsewhere, pulmonary edema with preserved
ejection fraction and worsening renal function during
therapy with an angiotensin converting enzyme inhibitor
(ACEI) or angiotensin receptor blocker (ARB). Recurrent
ﬂash pulmonary edema due to bilateral renal artery stenosisInternational Journal of Hypertension 3
is dangerous for the patient and should prompt considera-
tion of renal revascularization by angioplasty and stenting
[14].
3.RenalNerveActivation
Intense renal eﬀerent nerve stimulation causes renal vaso-
constriction with decreases in renal blood ﬂow (RBF) and
increases in renal vascular resistance (RVR). However, more
subtle increases in renal nerve activity increase renal tubular
sodium reabsorption and increase renin secretion without
changes in renal hemodynamics [15]. Renal nerves make
functional contact with many parts of the nephron including
the tubules and the juxtaglomerular apparatus, where these
eﬀects are manifest. The eﬀects of renal nerve stimulation
on renin secretion are direct and not secondary to volume
depletion or hemodynamic changes.
Renal denervation decreased blood pressure in many
animalmodelsofhypertension.Butthismaybearesponseto
preventing renal nerve traﬃc from the kidney (deaﬀerenta-
tion) and/or to the kidney (deeﬀerentation).
The renal aﬀerent sensory nerves are located primarily
in the renal pelvic wall where they exhibit mechanosensi-
tive (responding to increases in renal pelvic pressure) or
chemosensitive (responding to changes in chemical compo-
sition of the urine) properties. Physiological stimulation of
renal aﬀerentmechanosensitivenervesbyincreasinguretero-
pelvic pressure increased aﬀerent renal nerve activity and
decreased eﬀerent renal sympathetic nerve activity, resulting
in a diuresis and natriuresis. This was termed the renorenal
reﬂex [16]. Selective interruption of the aﬀerent pathway
has been achieved by removal of the kidney (presumed
source of the signal) or section of the dorsal roots conveying
aﬀerent renal nerve input to the neuraxis (T9-L1). Dorsal
root section reduced the blood pressure in rat models of
renovascular hypertension, which testiﬁes to the importance
of the renal aﬀerent nerves in maintaining hypertension in
this setting.
Muscle sympathetic nerve activity and calf muscle vas-
cular resistance were increased in patients with hypertension
receiving hemodialysis therapy [17]. Bilateral nephrectomy
abolished these changes. This important study identiﬁed
the chronically diseased kidney as the source of aﬀerent
renal input resulting in increased muscle sympathetic nerve
activity, calf vascular resistance, and hypertension.
A proof of concept study in 45 patients with resistant
hypertension reported that renal sympathetic denervation
by renal artery radiofrequency ablation reduced the BP by
24/10mmHg at 3 months and 29/16mmHg at 12 months
[18]. It is not clear whether this remarkable eﬀect of renal
nerve ablation on reducing BP is due to deaﬀerentation
or deeﬀerentation of the renal nerves, or a combination of
those. Symplicity HTN-2 trial [19] assessed 106 patients
with treatment-resistant hypertension (i.e., systolic blood
pressure ≥160mmHg or ≥150mmHg for patients with
diabetes despite the use of three or more antihypertensive
drugs).Patientswererandomlyassignedtorenalsympathetic
denervation (52) or control (54) groups. Renal denervation
resulted in impressive reductions in mean oﬃce-based mea-
surements of blood pressure (32/12mmHg at 6 months),
whereas blood pressure remained almost unchanged in the
control group. Home and ambulatory measurements of
blood pressure followed a similar pattern; the correspond-
ing reductions were 20/12mmHg and 11/7mmHg with
renal denervation, whereas no signiﬁcant reductions were
observed in the control group. However, there were several
limitations of the study design. The control group could
not undergo sham operation, which would have provided
double-blinding and reduced potential bias. Furthermore,
secondary and white-coat hypertensions were not deﬁned as
exclusion criteria.
The increase in renin secretion with renal nerve stimula-
tion is mediated via beta-1 receptors and is therefore blocked
by cardioselective and noncardioselective beta blockers. The
increaseintubularreabsorptionandrenalvascularresistance
aremediatedviaalphareceptorsandarediminishedbyalpha
blockers. Central agents such as clonidine reduce renal nerve
activity and renin secretion. Thus, several drugs used to treat
hypertension interrupt some of the renal mechanisms that
underlie resistant hypertension.
4. Nitric Oxide Deﬁciency
Studies in rodents have established that inhibition of nitric
oxidesynthase(NOS)causessystemicandglomerularhyper-
tension, glomerular ischemia, glomerulosclerosis, tubuloint-
erstitial injury, and proteinuria [20].
Most evidence suggests a decreased total nitric oxide
(NO) production in human renal disease and hypertension.
NO deﬁciency occurs in the presence of oxidative stress,
due both to inactivation of NO by superoxide anion and
to uncoupling of nitric oxide synthase, which then produces
superoxide rather than NO. There is evidence that oxidative
stress occurs early in the course of CKD and hypertension
and is ampliﬁed as the disease progresses [21].
Oxidative stress can precede the development of hyper-
tension and cause nitric oxide (NO) deﬁciency [22]. In a
study of patients with early essential hypertension, Wang
et al. [21] reported severe endothelial dysfunction and inhi-
bitionofmicrovascularnitricoxidesynthaseaccompaniedby
elevated plasma reactive oxygen species and elevated plasma
levels of asymmetric dimethyl arginine that can inhibit and
uncouple nitric oxide synthase [23].
In almost all rodent models of hypertension, there is
oxidative stress that if corrected, lowers BP, whereas creation
ofoxidative stressinnormalanimals cancausehypertension.
Reactive oxygen species (ROS) can enhance aﬀerent arteri-
olar tone and reactivity both indirectly via potentiation of
the tubuloglomerular feedback mechanism [24] and directly
by microvascular mechanisms that diminish endothelium-
derived relaxation factor/nitric oxide responses, generate
a cyclooxygenase-2-dependent endothelial-derived contract-
ing factor that activates thromboxane-prostanoid receptors,
[25] and enhance vascular smooth muscle cells reactivity
[26].DrugsthatimproveNOactivityinbloodvesselsinclude
nebivolol, nitrates and bidil. The hydralazine component in4 International Journal of Hypertension
bidil may act as a vascular antioxidant that preserves the
NO generated by the nitrate component. It has been used
primarily to treat resistant heart failure in African Amer-
icans. In a randomized, placebo-controlled, double blind
study involving six subjects, Oliver et al. [27] showed that the
combination of phosphodiesterase type 5 inhibitor, sildenaﬁl
and isosorbide mononitrate decreased BP by 26/18mmHg
as compared with placebo. However, it should not be forgot-
ten that sildenaﬁl has been considered to be contraindicated
in patients taking nitrates. Therefore, further evidence will
be needed before this new therapeutic combination can be
recommended for treatment of hypertension.
5. Medications Acting Adverselyon the Kidney
5.1. Nonsteroidal Anti-Inﬂammatory Drugs (NSAIDs).
NSAIDs are an important remediable cause of drug-
resistant hypertension. They increase BP by an average of
5mmHg, but the eﬀect can be more pronounced in resistant
hypertension. They inhibit renal prostaglandin production,
decrease renal blood ﬂow and retain sodium [28]. They
diminish the BP-lowering eﬀect of all antihypertensive drug
classesexceptcalciumantagonists [29].TheeﬀectofNSAIDs
on BP is more pronounced in patients with CKD. Selective
cyclo-oxygenase-2 inhibitors have eﬀects generally similar to
those of NSAIDs [30].
5.2. Glucocorticoids. Glucocorticoids such as prednisone
induce a modest sodium and water retention but the
mechanism by which they increase BP is uncertain [31].
Corticosteroids with mineralocorticoid eﬀect (e.g., hydro-
cortisone, cortisone) produce signiﬁcant ﬂuid retention,
but even agents without mineralocorticoid activity (e.g.,
dexamethasone, betamethasone, and triamcinolone) can
exacerbate hypertension in susceptible subjects. Licorice,
a common ingredient in oral tobacco products, can raise
blood pressure by suppressing the metabolism of cortisol
by beta hydroxysteroid dehydrogenase resulting in increased
stimulation of the mineralocorticoid receptor [32].
5.3. Erythropoietin StimulatingAgents(ESA). Erythropoietin
stimulating agents increased blood pressure in both nor-
motensive and hypertensive patients with CKD. Epogen may
raise BP by expanding blood volume, increasing the hema-
tocrit and hence the viscosity of the blood and increasing
vascular production of the vasoconstrictor prostaglandin,
thromboxane. However, in studies in rats these prohyperten-
sive eﬀects of epogen were oﬀset by increased NO generation
intheendothelialcellsofthekidney[33].SinceCKDimpairs
NO generation, this oﬀsetting eﬀect may be diminished and
this may explain why the hypertensive eﬀects of epogen are
more pronounced in patients with CKD and hypertension
[34].
5.4. Cyclosporine. As summarized in a Cochrane review, [35]
cyclosporine, in lower doses (1–4mg/kg/d) increases BP by
an average of 5mmHg and in higher doses (>10mg/kg/d)
by 11mmHg. The mechanisms are not established and
may include enhanced sympathetic nervous system activ-
ity, renal vasoconstriction, sodium/water retention, [36]
impaired peripheral vasodilatation and decreased vascular
compliance. Calcium channel blockers (CCBs) attenuate
cyclosporineinducedvasoconstriction[37].Verapamil,dilti-
azemandthedihydropyridinenicardipinereducethehepatic
metabolism of cyclosporine, thereby increasing its blood
level by 40–50%. Although some investigators have found
this interaction beneﬁcial as it leads to a reduction in the
dose of cyclosporine, other investigators prefer nifedipine
or isradapine, which have little eﬀect on blood levels of
cyclosporine or tacrolimus. Amlodipine has an intermediate
eﬀect on cyclosporine metabolism, and the dose does not
usually need adjustment [38].
6. Extra Renal FactorsCausingSaltRetention
6.1. Aldosterone. Aldosterone is secreted by the zona
glomerulosa of the adrenal cortex under the inﬂuence of
angiotensin II, potassium, metabolic acidosis and adreno-
corticotropic hormone (ACTH). The genomic pathway for
aldosterone action in tubular cells regulates the transport of
sodium and potassium. Aldosterone binds to mineralocorti-
coid receptors in the cytoplasm of the principal cells of the
collecting duct, which activate genes for speciﬁc protein syn-
thesis. This results in an increase in apical epithelial sodium
entry channels, basolateral sodium/potassium ATPase for
cellular sodium extrusion and potassium entry, and apical
ROMK channels for passive movement of cellular potassium
into the lumen that facilitates K+ secretion.
Thus, aldosterone promotes sodium reabsorption and
potassium secretion by the collecting ducts. Recent studies
have shown that aldosterone is important in resistant hyper-
tension. In the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) [39] of 1141 patients with resistant hypertension,
25mg daily of spironolactone over 1.3 years decreased the
mean systolic BP by 21.8mmHg and the diastolic BP by
9.5mmHg. Adverse eﬀects included gynecomastia or breast
tenderness (6%) and hyperkalemia (2%). In another study
of patients with resistant hypertension (mean baseline BP
163/91mmHg), spironolactone decreased BP to a similar
degree as the ASCOT trial. The decrements in systolic
and diastolic BP were similar to patients with primary
hyperaldosteronism [40] and were comparable in black
and white patients. Although much of the antihypertensive
eﬀect is likely secondary to reduced sodium reabsorption,
there is a nongenomic eﬀect mediated through the action
of spironolactone to block mineralocorticosteroid receptors
on the cell membranes of blood vessels. Evidence for a
nonrenal action comes from a study in which spironolactone
(50mg) twice daily reduced pre-dialysis systolic BP from
142 to 131mmHg in patients who had end stage renal
disease(ESRD)[41].Thesepatientshadanuriaandtherefore
the eﬀect of spironolactone must have been independent
of changes in sodium balance by the kidneys. Moreover,
aldosterone can injure the vascular endothelium, which
could contribute to elevated BP. Amiloride is a potassium-
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in patients with resistant hypertension. Eplerenone is a
more selective aldosterone antagonist than spironolactone
and is a good choice for patients who have responded
to spironolactone, but developed adverse eﬀects of breast
enlargement or loss of libido.
6.2. Vasodilatory Edema. Drug-induced edema with va-
sodilatory drugs can involve nonrenal mechanisms, in-
cluding direct arteriolar dilatation (causing an increase in
intracapillary pressure) in addition to stimulation of the
RAAS and renal ﬂuid retention. Vasodilatory edema is most
commonly encountered with direct arteriolar dilators such
as minoxidil or hydralazine, but also with dihydropyridine
calcium antagonists and alpha-blockers. The addition of an
ACE inhibitor or an ARB to a dihydropyridine calcium
antagonistreducedvasodilatoryedema,whereastheaddition
of a diuretic had little eﬀect [42].
6.3.ObstructiveSleepApnea(OSA). OSAcausesintermittent
hypoxemia and increased upper airway resistance that can
increase sympathetic nervous system activity, [43]r a i s e
blood pressure and increase ﬂuid retention. OSA has been
associated with increased reactive oxygen species with con-
comitant reduction in nitric oxide bioavailability and with
an increase in serum aldosterone [44]. A recent open-label
study provided preliminary evidence that treatment with a
mineralocorticoid receptor antagonist substantially reduced
the severity of OSA [45]. Importantly this treatment also
reduced the BP of these patients.
6.4. Endothelin Type A (ET-A) Receptor Antagonists. Cir-
culating endothelin-1 is elevated in patients with essential
hypertension [46]. The selective ET-A antagonist darusentan
reduced mean oﬃce blood pressure (systolic/diastolic) by
18/10mmHg [47]. Adverse events of ﬂuid retention and
edema occurred in 14% of patients in the placebo group,
25% in the 50-mg group, 32% in the 100-mg group, and
25% in the 300-mg group. The mechanism of ﬂuid retention
is unclear, but may involve renal sodium retention. In a
recenttrial[48],darusentandecreasedclinic systolicBPat14
weeks by 15mm hg ± 14mmHg as compared to guanfacine
(12 ± 13mmHg; P<. 0 5 ) .H o w e v e r ,a n a l y s i so fa m b u l a t o r y
blood pressure concluded that darusentan reduced mean 24-
hour systolic BP (9 ± 12mmHg) more than placebo (2 ±
12mmHg) or guanfacine (4 ± 12mmHg). Unfortunately,
the study was considered to be negative because it did not
meet the prespeciﬁed goal of reducing oﬃce blood pressure,
although the drug did have a clear-cut eﬀect in reducing
ambulatory blood pressure, whether compared to placebo or
to active control.
7.ExcessiveSaltIntake
Excessive dietary salt intake contributes to the development
of resistant hypertension both by increasing blood pressure
and by blunting the blood pressure lowering eﬀects of most
classes of antihypertensive agents, [49] including diuretics.
These eﬀe c t sa r em o r ep r o n o u n c e di ns o m es u b j e c t sw h o
are termed salt-sensitive. Salt sensitivity is more common
in the elderly, African Americans and in patients with CKD.
Among patients referred to a university hypertension center
for resistant hypertension, the average dietary salt ingestion
based on 24-hour urinary sodium excretion exceeded 10g or
(230mmol of sodium) a day [50].
Sodium intake should be assessed from sodium excretion
in a 24-hour urine collection. Urine sodium: creatinine
ratio is inaccurate since sodium excretion varies during
the day. Dietary sodium reduction to less than 3g/day is
associated with modest BP reductions, which are larger in
African-American and elderly patients. Current guidelines
suggestthat dietary sodium for a hypertensive patient should
be less than 100mmol/day (2.4g sodium or 6g sodium
chloride) [51]. This guideline is applicable to all patients
with resistant hypertension. Pimenta et al. [52]r a n d o m i z e d
twelvesubjectswithresistanthypertensiontolowversushigh
sodium diet (50 versus 250mmol daily for 7 days). The low
compared to the high salt diet decreased oﬃce systolic and
diastolic blood pressure by 22.7 and 9.1mmHg, respectively.
Further reductions in dietary salt can produce further
antihypertensive eﬀects, but are not usually practicable.
8. Ineffective DiureticUsage
T h ec o r r e c tu s eo fd i u r e t i c si sac r i t i c a ls t e pi nt h em a n -
agement of resistant hypertension. Diuretics not only reduce
ECF volume but also potentiate the eﬀects of ACE inhibitors,
ARBs,andotherantihypertensiveagents.Basedontheresults
of the ALLHAT trial, JNC 7 recommended thiazide diuretics
as preferred agents in the general population with essential
hypertension to lower blood pressure and reduce CVD risk
[51].
There are three major classes of diuretics: thiazides,
loop diuretics, and potassium-sparing agents. The choice of
diureticagentsdependsonthelevelofGFR,electrolytestatus
and the degree of ECV expansion [53].
Thiazide diuretics inhibit the apical Na+-Cl− cotransport
system in the ﬁrst part of the distal tubule. Thiazides
given once daily are recommended in patients with GFR
≥30mL/min/1.73m2. Chlorthalidone was used in a dose
range of 12.5 to 25mg/d in the ALLHAT trial. It is
longer-actingthanhydrochlorothiazide(HCTZ),resultingin
better blood pressure control, but also a higher incidence
of hypokalemia. A small study of patients with resistant
hypertension demonstrated that switching from the same
dose of hydrochlorothiazide to chlorthalidone resulted in an
additional 8mmHg drop in systolic BP and increased the
number of subjects at goal [54]. Chlorthalidone in a daily
dose of 25mg provided greater ambulatory BP reduction,
withthelargerdiﬀerenceoccurringovernightcomparedwith
hydrochlorothiazide 50mg [55].
T h i a z i d e sb e c o m em o r ee ﬀective in subjects accommo-
dated to loop diuretics likely because of functional and
structural hypertrophy of the early distal tubule. Thus, this
segment becomes of great importance for sodium reabsorp-
tion and thiazide drugs acting at this site therefore have
increased natriuretic eﬃcacy [56]. However, any increase in6 International Journal of Hypertension
sodium chloride (NaCl) delivery to the collecting duct can
increase distal sodium retention via the epithelia sodium
channel (ENaC) which enhances the luminal electronegative
potential and therefore enhances potassium (K+)s e c r e t i o n .
This can be countered by use of a distal, potassium-sparing
diuretic or a mineralocorticosteroid antagonist.
Metolazone and thiazide diuretics retain some eﬀective-
ness at GFR levels below 30mL/min/1.73m2.M e t o l a z o n ei s
used primarily for resistant edema in patients receiving loop
diuretics.
If blood pressure control worsens, or if volume expan-
sion occurs as CKD progresses during treatment with a
thiazide diuretic, a loop diuretic should be substituted [57].
Furosemide or bumetanide should be given twice daily, as
they have short durations of actions of 3 to 6 hours, although
these are increased in patients with renal impairment [58].
Torsemide is longer acting and is eliminated by hepatic
metabolism. Therefore, it does not accumulate in renal
insuﬃciency. It may be preferable with patients with CKD.
The natriuretic eﬀects of loop diuretics are oﬀset by post-
diuretic sodium retention [59]. Patients with advanced CKD
(GFR <30mL/min) who are unresponsive to thiazide alone
have a marked natriuresis when a loop diuretic is added,
[60] probably by blockade of enhanced distal tubular Na+
reabsorption. However, such combination therapy should be
initiated under close surveillance because of a high incidence
of hypokalemia, excessive ECV depletion, and azotemia [61].
There are two principal classes of potassium-sparing
diuretics, those that inhibit epithelial sodium channels
(triamtereneandamiloride)andthosethatinhibitmineralo-
corticoid receptors (aldosterone and eplerenone). For both
types, the site of action is in the collecting tubule.
The role of spironolactone in resistant hypertension
[62] was discussed earlier. Addition of spironolactone to
therapy with other diuretics should always be considered
in patients with drug-resistant hypertension providing that
there is no hyperkalemia. Serum potassium must be moni-
tored regularly during drug therapy. If adverse eﬀects such
as gynecomastia or breast tenderness develop, eplerenone
should be substituted as it lacks progesterogenic and
antiandrogeniceﬀects.AcombinationofHCTZ/Triamterene
or HCTZ/Amiloride is very eﬀective [63], produces less
hypokalemia than HCTZ alone and should be considered
in patients with a GFR of >30mL/min/1.73m2. Hood
et al. [64], crossed over 51 patients with primary hyperaldos-
teronism between normal and high-dose therapy with ben-
droﬂumethazide, amiloride or spironolactone. Remarkably,
when used at high-dose, the drugs were equally eﬀective in
reducing the blood pressure.
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